Toni L Pitcher

List of Publications by Year
in descending order

32 papers	3,359 citations	430874 18 h-index	434195 31 g-index
37 all docs	37 docs citations	37 times ranked	6330 citing authors

#	Article	IF	Citations
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
2	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	12.6	450
3	Grey matter atrophy in cognitively impaired Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 188-194.	1.9	211
4	Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. Genome Medicine, 2019, 11, 54.	8.2	191
5	Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain, 2011, 134, 845-855.	7.6	173
6	White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology, 2013, 80, 1841-1849.	1.1	129
7	Analysis of DNA methylation associates the cystineâ€“glutamate antiporter SLC7A11 with risk of Parkinsonâ€™s disease. Nature Communications, 2020, 11, 1238.	12.8	85
8	Reduced striatal volumes in Parkinsonâ€™s disease: a magnetic resonance imaging study. Translational Neurodegeneration, 2012, 1, 17.	8.0	81
9	Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. Nature Communications, 2020, 11, 4796.	12.8	61
10	The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson's disease. Neuropsychologia, 2012, 50, 3338-3347.	1.6	60
11	Different PD-MCI criteria and risk of dementia in Parkinsonâ€™s disease: 4-year longitudinal study. Npj Parkinson's Disease, 2016, 2, 15027.	5.3	55
12	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. Movement Disorders, 2021, 36, 2583-2594.	3.9	54
13	Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease. Frontiers in Neurology, 2019, 10, 391.	2.4	50
14	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
15	Caregiver burden is increased in Parkinsonâ€™s disease with mild cognitive impairment (PD-MCI). Translational Neurodegeneration, 2017, 6, 17.	8.0	35
16	Extracellular vesicle biomarkers for cognitive impairment in Parkinsonâ€™s disease. Brain, 2023, 146, 195-208.	7.6	35
17	Common Variants Coregulate Expression of <scp>GBA</scp> and Modifier Genes to Delay Parkinson's Disease Onset. Movement Disorders, 2020, 35, 1346-1356.	3.9	30
18	Enhanced highâ€frequency membrane potential fluctuations control spike output in striatal fastâ€spiking interneurones in vivo. Journal of Physiology, 2011, 589, 4365-4381.	2.9	22

#	Article	IF	Citations
19	Parkinsonâ€™s in the oldest old: Impact on estimates of future disease burden. Parkinsonism and Related Disorders, 2017, 42, 78-84.	2.2	21
20	Tracking Parkinsonâ€™s Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease. PLoS ONE, 2015, 10, e0143923.	2.5	21
21	Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting. Parkinsonism and Related Disorders, 2016, 22, 54-61.	2.2	20
22	Brain activation during processing of genuine facial emotion in depression: Preliminary findings. Journal of Affective Disorders, 2018, 225, 91-96.	4.1	18
23	Parkinson's disease across ethnicities: A nationwide study in New Zealand. Movement Disorders, 2018, 33, 1440-1448.	3.9	17
24	Nanopore sequencing of the glucocerebrosidase (GBA) gene in a New Zealand Parkinson's disease cohort. Parkinsonism and Related Disorders, 2020, 70, 36-41.	2.2	17
25	A Multiâ€Step Model of Parkinson's Disease Pathogenesis. Movement Disorders, 2021, 36, 2530-2538.	3.9	13
26	Neuropsychiatric Symptoms Are Associated with Dementia in Parkinson's Disease but Not Predictive of it. Movement Disorders Clinical Practice, 2021, 8, 390-399.	1.5	9
27	Positive Association of Ascorbate and Inverse Association of Urate with Cognitive Function in People with Parkinsonâ€™s Disease. Antioxidants, 2020, 9, 906.	5.1	8
28	Differences in striatal spiny neuron action potentials between the spontaneously hypertensive and Wistar-Kyoto rat strains. Neuroscience, 2007, 146, 135-142.	2.3	7
29	Changes of plasma cGP/IGFâ€1 molar ratio with age is associated with cognitive status of Parkinson disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12025.	2.4	5
30	Variations in the patterns of prevalence and therapy in Australasian Parkinsonâ€™s disease patients of different ethnicities. BMJ Neurology Open, 2020, 2, e000033.	1.6	5
31	Childbirth and Delayed Parkinson's Onset: A Reproducible Nonbiological Artifact of Societal Change. Movement Disorders, 2020, 35, 1268-1271.	3.9	2
32	Higher perceived stress and exacerbated motor symptoms in Parkinson's disease during the COVID-19 lockdown in New Zealand. New Zealand Medical Journal, 2021, 134, 44-51.	0.5	0